The authors sought to determine whether MM with adverse cytogenetic would benefit greater to Pom-Dex if exposed earlier in the multicenter IFM 2010-02. Pomalidomide plus low dose dexamethasone, a doublet IMiDs-based regimen, is active and well tolerated in adverse cytogenetic patients with early RRMM, particularly with del(17p), characterized with high and rapid development of a refractoriness state, and known for their poor prognosis.

READ FULL ARTICLE Curated publisher From Mdlinx